GLYCOBIOM
Tools for the Detection of Novel Glyco-biomarkers
| Coordinatore | THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 6˙806˙915 € |
| EC contributo | 5˙199˙099 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | coordinator | 1˙552˙967.25 |
| 2 |
National Institute for Bioprocessing Research and Training Ltd
Organization address
address: "Engineering Building, Belfield 125" contact info |
IE (Dublin) | participant | 1˙097˙230.75 |
| 3 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | participant | 838˙700.00 |
| 4 |
GENOS DOO ZA VJESTACENJE I ANALIZU
Organization address
address: Vatrogasna 112 contact info |
HR (Osijek) | participant | 627˙802.00 |
| 5 | KOBENHAVNS UNIVERSITET | DK | participant | 602˙399.00 |
| 6 |
GALAB LABORATORIES GMBH
Organization address
address: MAX PLANCK STRASSE 1 contact info |
DE (GEESTHACHT) | participant | 480˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Glycosylation patterns on glycoproteins and glycolipids are involved in the regulation of inter- and intracellular recognition events and alteration of such glycosylation has been observed in many diseases, notably in a variety of cancers. We propose that a systematic, large scale investigation in this area will provide a rich spectrum of novel and structurally diverse carbohydrate-based highly specific biomarkers. The aim of this project will be to address current bottlenecks in analytical techniques by developing an integrated multidisciplinary approach to glycobiomarker screening and analysis based on current state-of-the-art. We will bring together a number of complementary screening techniques developed in the individual partner laboratories, notably high-throughput LC-ms analysis of carbohydrates, lectins and carbohydrate arrays, to develop an overall workflow for the multiplex analysis of glycobiomarkers. Such carbohydrate-targeted methods will be combined with RNA/DNA and analysis (combining high throughput glycomics with genomics). It will be important to test the workflow against serum and tissue samples of healthy volunteer/cancer patients. In addition, we envisage that the project will generate new analytical tools that can be used in routine analysis of glycobiomarkers in the clinic, including diagnostic imaging. Some of the tools developed in this programme (lectins conjugated to nonoparticles) should also be useful for new quantitative imaging biomarkers for monitoring therapeutic effects and safety in cancer. The involvement of three SME partners will ensure that the technology is compatible with commercial applications.'